View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 14, 2021updated 07 Jan 2022 5:52am

Samsung Biologics and AstraZeneca expand deal to include Covid-19 treatment

Under the $380m deal, Samsung Biologics manufactures AstraZeneca’s antibody cocktail, AZD7442.

Samsung Biologics and AstraZeneca have expanded a strategic biopharmaceutical production partnership to include therapies for Covid-19 and cancer.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The latest collaboration is based on an agreement initially expanded in May.

In September 2020, the companies had entered a long-term strategic deal worth nearly $330.8m for manufacturing the drug substance and product.

According to the latest deal worth nearly $380m, Samsung Biologics produces a Covid-19 long-acting antibody (LAAB) cocktail of AstraZeneca, AZD7442.

A combination of two LAABs, AZD7442 is being developed to prevent and treat Covid-19.

It has obtained the US Food and Drug Administration (FDA) emergency use authorization (EUA) for preventing the disease and is also authorised for use in Italy, France and Bahrain.

Immunocompromised individuals, patients receiving dialysis, cancer patients, those who have had an organ transplant, or people under immunosuppressive therapies could benefit from the antibody cocktail, the company said.

Additionally, Samsung Biologics will commence the production of a cancer immunotherapy product next year.

AstraZeneca Global Operations and IT executive vice-president Pam Cheng said: “Over the past year, Samsung Biologics has been a highly capable and collaborative partner on our novel Covid-19 long-acting antibody combination.

“We are excited about expanding our work together into cancer immunotherapy and about laying the foundation for the continued growth of our collaboration in the years ahead.”

Samsung Biologics is setting up a plant, which, on completion, will permit the firm to have a 620,000l biomanufacturing capacity.

It has also incorporated a messenger RNA vaccine drug substance production suite to its Songdo plant, which will be equipped for cGMP operations earlier next year.

In another development, the Ministry of Food and Drug Safety of Korea (MFDS) granted marketing authorization for Moderna’s Covid-19 vaccine, Spikevax, produced at Samsung Biologics’ manufacturing sites.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology